Here are the 10-K annual reports from Quantum-Si Incorporated (QSI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QSI filings page.
Quantum-Si Incorporated is an early-stage life sciences technology company focused on proteomics, aiming to make single-molecule protein sequencing widely accessible. It has developed its Platinum and higher-priced Platinum Pro next-generation protein sequencing instruments, sold with proprietary library preparation and sequencing kits plus Platinum Analysis Software.
The company targets research-use-only applications today, positioning its platform as a lower-cost, automated alternative and complement to legacy mass spectrometry and affinity-based methods. Management describes a large addressable market within a broader proteomics opportunity and plans to drive recurring consumables revenue from a growing installed base. A major roadmap milestone is the Proteus platform, expected to launch by the end of 2026 with much higher feature density and automation. Key risks include continued net losses and funding needs, potential delays or underperformance of Proteus, dependence on single-source contract manufacturers and semiconductor processes, evolving data, privacy and healthcare regulations, and governance factors such as controlled-company status, dual-class stock and the need to maintain Nasdaq listing.